Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Gerber DE, Camidge DR, Morgensztern D, Cetnar J, Kelly RJ, Ramalingam SS, Spigel DR, Jeong W, Scaglioni PP, Zhang S, Li M, Weaver DT, Vaikus L, Keegan M, Horobin JC, Burns TF.
Gerber DE, et al. Among authors: horobin jc.
Lung Cancer. 2020 Jan;139:60-67. doi: 10.1016/j.lungcan.2019.10.033. Epub 2019 Nov 4.
Lung Cancer. 2020.
PMID: 31739184
Free PMC article.
Clinical Trial.